Success Stories: NAILG Helps Cardiologist Earn EB1A Approval for Contributions to Heart Care
Client’s Testimonial:
“Fantastic professionals who do an amazing job. Very thorough and detail oriented. Guided us throughout the process explaining the pros and cons at every step. Highly recommend without reservations.”
On October 7th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for an Interventional Cardiologist in the field of Cardiovascular Diseases (Approval Notice).
General Field: Cardiovascular Diseases
Position at the Time of Case Filing: Interventional Cardiologist
Country of Origin: India
State of Residence at the Time of Filing: Missouri
Approval Notice Date: October 7th, 2025
Processing Time: 3 months (Premium Processing Requested)
Case Summary:
Heart disease remains one of the most pressing global health challenges, and our client has devoted his career to finding better ways to treat and prevent it. As a cardiologist and researcher specializing in interventional and structural heart disease, he has played a pivotal role in improving treatment outcomes for patients with complex cardiovascular conditions. With the support of the North America Immigration Law Group (NAILG), his EB1A (Alien of Extraordinary Ability) petition was approved, recognizing his groundbreaking work and enduring impact on public health.
Our client’s research has redefined care for patients with pulmonary embolism, heart valve disorders, and stroke risk following valve replacement procedures. His studies have led to safer and more effective therapeutic approaches while also advancing transparency in the relationship between the medical community and the biomedical industry.
As one expert noted, “[Client]’s skillset is important and unusual, providing significant benefits to improving treatment protocols for pulmonary embolism, advancing patient survival rates, and enhancing the development of minimally invasive therapies.”
His academic record reflects both depth and influence. He has authored 24 peer-reviewed journal articles and 20 conference abstracts, including 11 and 6 as first or co-first author, respectively. His research has been cited 436 times in leading medical journals. In addition, he has completed 27 peer reviews for top-tier publications, contributing to the advancement and integrity of global cardiovascular research.
NAILG emphasized these accomplishments in demonstrating that our client is among the top experts in his field, an innovator whose ongoing work strengthens the United States’ capacity for medical research and healthcare excellence. His EB1A approval highlights not only his individual achievement but also NAILG’s success in advocating for scientists whose work directly enhances patient outcomes and public well-being.

